Home LiteratureArticle Details
PMID: 8649388 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Inhibition of cell proliferation by the Mad1 transcriptional repressor.

Molecular and cellular biology ·Vol. 16 ·No. 6 ·1996-06-00 ·Pages 2796-801

Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE

Abstract

Mad1 is a basic helix-loop-helix-leucine zipper protein that is induced upon differentiation of a number of distinct cell types. Mad1 dimerizes with Max and recognizes the same DNA sequences as do Myc:Max dimers. However, Mad1 and Myc appear to have opposing functions. Myc:Max heterodimers activate transcription while Mad:Max heterodimers repress transcription from the same promoter. In addition Mad1 has been shown to block the oncogenic activity of Myc. Here we show that ectopic expression of Mad1 inhibits the proliferative response of 3T3 cells to signaling through the colony-stimulating factor-1 (CSF-1) receptor. The ability of over-expressed Myc and cyclin D1 to complement the mutant CSF-1 receptor Y809F (containing a Y-to-F mutation at position 809) is also inhibited by Mad1. Cell cycle analysis of proliferating 3T3 cells transfected with Mad1 demonstrates a significant decrease in the fraction of cells in the S and G2/M phases and a concomitant increase in the fraction of G1 phase cells, indicating that Mad1 negatively influences cell cycle progression from the G1 to the S phase. Mutations in Mad1 which inhibit its activity as a transcription repressor also result in loss of Mad1 cell cycle inhibitory activity. Thus, the ability of Mad1 to inhibit cell cycle progression is tightly coupled to its function as a transcriptional repressor.

MeSH Terms
3T3 Cells Animals Carrier Proteins Cell Cycle/drug effects,genetics Cell Cycle Proteins Cell Division/drug effects,genetics Cyclin D1 Cyclins/pharmacology Humans Macrophage Colony-Stimulating Factor/pharmacology Mice Nuclear Proteins/genetics Oncogene Proteins/pharmacology Phosphoproteins/genetics Point Mutation Proto-Oncogene Proteins c-myc/pharmacology Receptor, Macrophage Colony-Stimulating Factor/genetics Repressor Proteins/genetics Transfection
Chemicals
Carrier Proteins Cell Cycle Proteins Cyclins MAD1L1 protein, human Mad1l1 protein, mouse Nuclear Proteins Oncogene Proteins Phosphoproteins Proto-Oncogene Proteins c-myc Repressor Proteins Cyclin D1 Macrophage Colony-Stimulating Factor Receptor, Macrophage Colony-Stimulating Factor
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Roussel M F
Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Ashmun R A
Sherr C J
Eisenman R N
Ayer D E
References (43)
43 references, click to expand
  1. Mutation of the MXI1 gene in prostate cancer.
    Nat Genet. 1995 Mar;9(3):249-55 PMID: 7773287
  2. The MYC protein activates transcription of the alpha-prothymosin gene.
    EMBO J. 1991 Jan;10(1):133-41 PMID: 1989881
  3. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Oncogene. 1995 Aug 3;11(3):587-96 PMID: 7630643
  4. Cloning and characterization of murine p16INK4a and p15INK4b genes.
    Oncogene. 1995 Aug 17;11(4):635-45 PMID: 7651726
  5. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
    Cell Growth Differ. 1995 Jun;6(6):623-9 PMID: 7669717
  6. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Mol Cell Biol. 1991 Apr;11(4):1785-92 PMID: 2005881
  7. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling.
    Nature. 1991 Sep 26;353(6342):361-3 PMID: 1833648
  8. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc.
    Cell. 1992 Jul 10;70(1):57-67 PMID: 1535827
  9. Myc and Max function as a nucleoprotein complex.
    Curr Opin Genet Dev. 1992 Apr;2(2):227-35 PMID: 1638116
  10. Mitosis-specific phosphorylation of the nuclear oncoproteins Myc and Myb.
    J Cell Biol. 1992 Aug;118(4):775-84 PMID: 1500422
  11. p53 function and dysfunction.
    Cell. 1992 Aug 21;70(4):523-6 PMID: 1505019
  12. The functions of Myc proteins.
    Biochim Biophys Acta. 1992 Dec 16;1114(2-3):129-46 PMID: 1457461
  13. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
    Cell. 1993 Jan 29;72(2):211-22 PMID: 8425218
  14. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
    Cell. 1993 Jan 29;72(2):223-32 PMID: 8425219
  15. Cyclin D1 is a nuclear protein required for cell cycle progression in G1.
    Genes Dev. 1993 May;7(5):812-21 PMID: 8491378
  16. Cell cycle regulation of the c-Myc transcriptional activation domain.
    Mol Cell Biol. 1993 Jul;13(7):4125-36 PMID: 8321217
  17. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
    Genes Dev. 1993 Aug;7(8):1559-71 PMID: 8339933
  18. Production of high-titer helper-free retroviruses by transient transfection.
    Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6 PMID: 7690960
  19. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
    Genes Dev. 1993 Nov;7(11):2110-9 PMID: 8224841
  20. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  21. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.
    Mol Cell Biol. 1994 Mar;14(3):1669-79 PMID: 8114703
  22. Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc.
    Oncogene. 1994 Apr;9(4):1247-52 PMID: 8134128
  23. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.
    Curr Opin Genet Dev. 1994 Feb;4(1):102-8 PMID: 8193530
  24. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1.
    Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5503-7 PMID: 8202517
  25. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD.
    Science. 1995 Feb 17;267(5200):1018-21 PMID: 7863327
  26. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells.
    Science. 1995 Feb 17;267(5200):1024-7 PMID: 7863329
  27. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3.
    Cell. 1995 Mar 10;80(5):767-76 PMID: 7889570
  28. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3.
    Cell. 1995 Mar 10;80(5):777-86 PMID: 7889571
  29. Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro.
    J Cell Biol. 1995 Mar;128(6):1197-208 PMID: 7896882
  30. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells.
    Oncogene. 1995 Apr 20;10(8):1659-65 PMID: 7731722
  31. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  32. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.
    Mol Cell Biol. 1995 May;15(5):2672-81 PMID: 7739547
  33. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells.
    Nat Med. 1995 Jul;1(7):638-43 PMID: 7585143
  34. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.
    EMBO J. 1995 Nov 15;14(22):5646-59 PMID: 8521822
  35. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.
    Oncogene. 1995 Dec 21;11(12):2487-501 PMID: 8545105
  36. Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts.
    J Clin Invest. 1984 Jun;73(6):1617-28 PMID: 6233301
  37. Levels of c-myc oncogene mRNA are invariant throughout the cell cycle.
    Nature. 1985 Mar 28-Apr 3;314(6009):363-6 PMID: 3982504
  38. c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells.
    Nature. 1985 Mar 28-Apr 3;314(6009):366-9 PMID: 3885045
  39. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor).
    Nature. 1987 Feb 5-11;325(6104):549-52 PMID: 3027579
  40. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1.
    Nature. 1987 Jul 30-Aug 5;328(6129):445-9 PMID: 3302722
  41. High-efficiency transformation of mammalian cells by plasmid DNA.
    Mol Cell Biol. 1987 Aug;7(8):2745-52 PMID: 3670292
  42. Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.
    Mol Cell Biol. 1988 Apr;8(4):1614-24 PMID: 2454393
  43. Rescue of defective mitogenic signaling by D-type cyclins.
    Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6837-41 PMID: 7624328
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1996-06-00
Pages
2796-801
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC231271
Subset
IM
Grants
NCI NIH HHS · CA20180 · United States
NCI NIH HHS · CA56819 · United States
NCI NIH HHS · CA57138 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com